Halozyme rockets 30% on potential $515M deal with Pfizer

Shares of Halozyme Therapeutics soared 30% on 21 December after it revealed it had inked a worldwide deal with Pfizer to develop and commercialize subcutaneous biologics using recombinant human hyaluronidase.